Page 171 of 440: studies 1,701 to 1,710 of 4,392, newest first. Back to the psilocybin overview
Bristol Research 2017 Paul J. May preprint
This is the Molecule of the Month entry for October 1999 about psilocybin and mescaline. It is a pdf archive version of the HTML webpage.
Mental Health Clinician 2017 Jeremy Daniel, Margaret Haberman 78 citations
Abstract Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of...
Asian Journal of Psychiatry December 1, 2016 Suravi Patra
Psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. The efficacy of psilocybin in clinical depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this...
Journal of Psychopharmacology November 30, 2016 Stephen Ross, Anthony P. Bossis, Jeffrey Guss et al. 1,699 citations
Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were...
Journal of Psychopharmacology November 30, 2016 Annie Umbricht, Mary P Cosimano, Roland R. Griffiths et al. 2,174 citations
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the...
Journal of Psychopharmacology November 18, 2016 Frederick S. Barrett, Matthew P. Bradstreet, Jeannie‐marie Leoutsakos et al. 364 citations
Acute adverse psychological reactions to classic hallucinogens (“bad trips” or “challenging experiences”), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood),...
Therapeutic Advances in Psychopharmacology October 27, 2016 Ananya Mahapatra, Rishi Gupta 37 citations
Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating...
Journal of Humanistic Psychology October 16, 2016 Michael P. Bogenschutz, Alyssa A. Forcehimes 96 citations
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, and promises to continue to expand. Experimental study of hallucinogen-assisted treatment, and any future clinical use, requires the development of psychotherapeutic models that are appropriate to the disorder being treated and effectively integrated...
Psychiatria i Psychologia Kliniczna September 30, 2016 Karolina Dydak, Mariola Śliwińska‐mossoń, Halina Milnerowicz 2 citations
Psylocybina jest substancją psychodysleptyczną pochodzenia naturalnego, występuje w grzybach rodzaju Psilocybe. Psychodysleptyki są środkami psychoaktywnymi, które silnie wpływają na percepcję, nastrój i procesy poznawcze człowieka. Psychodeliczne działanie psylocybiny opiera się na pobudzaniu receptorów serotoninergicznych, co prowadzi do wzrostu stężenia serotoniny w mózgu oraz przyczynia się...
PSYCH up2date September 8, 2016
Fazit Die vorliegende Studie gibt erste Hinweise auf eine Wirksamkeit von Psilocybin bei chronischen Depressionen. Weitere positive Effekte dieser Substanz konnten bereits in anderen Zusammenhängen nachgewiesen werden. Bei nun nachgewiesener, guter Machbarkeit, motivieren die Autoren zu weiteren kontrollierten Studien mit diesem Wirkstoff.